Ironwood Pharmaceuticals (IRWD) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.16 EPS for the quarter. Analysts had a consensus estimate of $-0.16. The company posted revenue of $54.40 million in the period, compared to analysts expectations of $54.49 million. The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.
Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Company shares were Reiterated by Mizuho on Jul 15, 2016 to “Buy”, Firm has raised the Price Target to $ 24 from a previous price target of $16 .Company shares were Reiterated by Mizuho on May 10, 2016 to “Buy”, Firm has raised the Price Target to $ 16 from a previous price target of $15 .
Ironwood Pharmaceuticals closed down -0.11 points or -0.79% at $13.83 with 12,66,020 shares getting traded on Tusday. Post opening the session at $13.94, the shares hit an intraday low of $13.675 and an intraday high of $14.2 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 6, 2016, Lawrence S Olanoff (director) sold 2,200 shares at $12.92 per share price. According to the SEC, on May 27, 2016, Halley E Gilbert (Chief Legal Officer) sold 20,275 shares at $12.19 per share price. On Mar 11, 2016, Peter M Hecht (Chief Executive Officer) sold 120,000 shares at $10.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.